Diagnosing bladder transitional cell carcinoma stage III requires a combination of tests and procedures to determine how far cancer has spread through the bladder wall and into surrounding tissues, helping doctors plan the most appropriate treatment path.

Introduction: Who Should Seek Diagnostic Testing

If you notice blood in your urine, even if it appears only once or comes and goes, it’s important to see a healthcare provider. Blood in the urine, also called hematuria, is usually the first noticeable sign of bladder cancer and should never be ignored, even if you feel otherwise healthy.^[1] When cancer reaches stage III, it means the disease has grown beyond the inner layers of the bladder and spread into deeper tissue, making early and accurate diagnosis essential for planning treatment.^[3]

People experiencing changes in how they urinate should also consider diagnostic testing. This includes feeling the urge to urinate more frequently than usual, experiencing pain or burning during urination, or having difficulty emptying the bladder completely. In more advanced stages like stage III, you might notice additional symptoms such as lower back pain on one side, unexplained weight loss, decreased appetite, ongoing fatigue, or swelling in your feet.^[3] These symptoms develop because the cancer has grown through the muscle layer of the bladder wall and may be affecting nearby organs.

Anyone with risk factors for bladder cancer should be particularly alert to symptoms. If you smoke cigarettes, work with certain industrial chemicals used in dyes, rubber, leather, paint, or textiles, or have previously been treated for bladder cancer, you face a higher risk of developing transitional cell carcinoma (also called urothelial carcinoma).^[1] Males are four times more likely to develop bladder cancer than females, and most people diagnosed are over age 65, though the disease can occur at any age.^[1]

When stage III bladder cancer is present, cancer has invaded through the connective tissue and muscle layers into the fat layer surrounding the bladder. In females, it may have spread to the uterus or vagina, while in males it may have reached the prostate gland or seminal vesicles.^[3] However, at this stage, the cancer has not yet spread to distant parts of the body like the lungs, liver, or bones. The sooner you seek diagnostic testing when symptoms appear, the more information your healthcare team will have to guide treatment decisions.

Diagnostic Methods for Identifying Stage III Bladder Cancer

When you first visit a healthcare provider with symptoms suggesting bladder cancer, they will begin with basic tests that help identify whether cancer is present and, if so, how advanced it is. The diagnostic process typically starts with examining a sample of your urine. A urinalysis checks for blood, infection, and other abnormalities in your urine.^[1] Your provider may also perform specialized tests looking specifically for cancer cells in your urine, although these cells may not always be detected even when cancer is present.

Imaging tests create detailed pictures of the inside of your body, allowing doctors to see tumors and assess their size and location. You may need a CT scan (computed tomography), which uses X-rays and computer technology to create cross-sectional images of your bladder and surrounding structures. An MRI (magnetic resonance imaging) uses powerful magnets and radio waves instead of radiation to produce detailed images of soft tissues. Ultrasound uses sound waves to create pictures and can help visualize the bladder and kidneys.^[1] These imaging techniques are particularly important for stage III diagnosis because they reveal whether cancer has grown through the bladder wall into surrounding fat and nearby organs.

A specialized imaging test called an intravenous pyelogram (IVP) may be recommended. During this procedure, a contrast dye is injected into your vein, which travels through your bloodstream to your kidneys, ureters, and bladder. The dye makes these organs stand out clearly on X-ray images, helping identify blockages or abnormalities that might indicate cancer spread.^[1] This test provides valuable information about the entire urinary system.

The most direct way to examine the inside of your bladder is through cystoscopy. During this procedure, your doctor inserts a thin tube with a light and lens, called a cystoscope, through your urethra (the tube that carries urine out of your body) into your bladder.^[9] This allows them to see the bladder lining directly and identify any tumors or abnormal areas. The procedure can be done in a doctor’s office or hospital, often with local anesthesia to minimize discomfort.

If abnormal tissue is found during cystoscopy, your doctor will take a biopsy, which means removing a small sample of tissue for laboratory examination. The tissue is examined under a microscope by a specialist called a pathologist, who can determine whether cancer cells are present and what type of cancer it is.^[1] For bladder cancer, this almost always reveals urothelial carcinoma, also called transitional cell carcinoma, which accounts for about 90% of all bladder cancers in the United States.^[1]

A procedure called transurethral resection of bladder tumor (TURBT) serves both diagnostic and treatment purposes. During TURBT, your surgeon uses a special instrument inserted through the urethra to remove visible tumor tissue from the bladder wall.^[13] This removed tissue is then examined to determine how deeply the cancer has invaded the bladder layers—a critical piece of information for staging. TURBT is often the first step in treating bladder cancer, but when it comes to diagnosis, it provides the most accurate information about tumor depth and characteristics.

After initial tests suggest cancer is present, your healthcare team needs to determine the stage—meaning how far the cancer has spread. This process is called staging and involves additional tests beyond the initial diagnosis. For stage III bladder cancer, doctors need to confirm that cancer has grown through the muscle layer into the fatty tissue surrounding the bladder or into nearby organs, but has not spread to distant parts of the body or lymph nodes far from the bladder.^[5]

The TNM staging system is the most common method for staging bladder cancer. In this system, T stands for tumor and describes how deeply cancer has invaded the bladder wall. N stands for nodes and indicates whether cancer has spread to lymph nodes. M stands for metastasis and shows whether cancer has spread to distant organs.^[5] Stage III bladder cancer is typically classified as T3 or T4a, meaning the tumor has grown through the bladder muscle into surrounding fat or nearby organs, but with N0 and M0, indicating no lymph node involvement or distant spread.

To fully evaluate stage III disease, your doctor may recommend imaging the lymph nodes in your pelvis and checking whether cancer has spread beyond the bladder region. A PET scan (positron emission tomography) uses a small amount of radioactive sugar that cancer cells absorb more readily than normal cells, making tumors show up on special cameras.^[12] This test can reveal cancer spread that other imaging might miss.

Blood tests provide additional information about your overall health and organ function. While blood tests don’t directly diagnose bladder cancer, they help your healthcare team understand how well your kidneys are working and whether cancer may be affecting other body systems. Complete blood counts check for anemia, which can result from bleeding tumors. Chemistry panels assess kidney and liver function, important information when planning treatment.^[9]

Diagnostics for Clinical Trial Qualification

When considering participation in a clinical trial for stage III bladder cancer, additional diagnostic tests may be required beyond those used for standard diagnosis and staging. Clinical trials test new treatments or combinations of existing therapies, and researchers need very specific information about your cancer to ensure the trial is appropriate for you and that results can be accurately interpreted.

Clinical trials typically require confirmation of your cancer stage through multiple methods. This means you will need documentation from imaging tests such as CT scans or MRI showing the extent of tumor growth through the bladder wall and into surrounding tissue. You may also need recent cystoscopy findings and pathology reports from tissue biopsies confirming the cancer type and grade.^[10] The grade describes how abnormal the cancer cells look under a microscope and how quickly they’re likely to grow.

Many clinical trials require that tissue samples be reviewed by the trial’s own pathologists to confirm the diagnosis and stage. This ensures all participants meet the same criteria. You may be asked to provide slides or tissue blocks from your original biopsy so they can be examined at a central laboratory. This process, called central pathology review, helps maintain consistency across all trial participants.

Blood tests are standard requirements for clinical trial enrollment. These establish baseline measurements of your overall health, kidney function, liver function, and blood cell counts. Researchers need to know your body is healthy enough to tolerate the trial treatment and to monitor how the treatment affects you over time.^[10] Some trials have specific requirements, such as minimum kidney function levels, because certain treatments are processed through the kidneys.

Genetic and molecular testing of tumor tissue has become increasingly important for clinical trial qualification. Some trials focus on patients whose tumors have specific genetic mutations or molecular characteristics. For example, certain trials may require testing for mutations in the FGFR2 or FGFR3 genes, as drugs targeting these specific changes are being studied.^[17] Your tumor tissue may be tested for these and other markers to determine whether you’re eligible for trials targeting specific molecular features.

Performance status assessment is another standard part of clinical trial screening. Your healthcare team will evaluate how well you can carry out daily activities using standardized scales. This helps researchers ensure participants are healthy enough for the trial and provides a baseline for measuring how treatment affects quality of life. Performance status considers factors like whether you can work, care for yourself, and spend time out of bed.

Imaging tests used for trial qualification often need to be performed within a specific time frame before enrollment, typically within a few weeks. This ensures the information accurately reflects your current condition. You may need to repeat CT scans, MRI, or other imaging even if you had them done recently for initial diagnosis. Some trials use specialized imaging protocols or require specific types of scans not typically used in standard care.

If you’ve received previous treatment for bladder cancer, detailed records of those treatments will be needed. Clinical trials often have specific requirements about prior therapies—some may require that you haven’t received certain treatments, while others specifically enroll patients whose cancer returned after standard treatment.^[10] Complete documentation of previous surgeries, chemotherapy, radiation, or other treatments helps researchers determine eligibility.

Urine tests may be required as part of clinical trial screening, particularly for trials testing new diagnostic methods or monitoring techniques. Some studies collect urine samples to look for specific proteins or genetic material shed by cancer cells. These biomarkers can help predict how cancer might respond to treatment or provide early warning of cancer recurrence.

Clinical trials may require additional biopsies beyond those done for diagnosis. Some studies need fresh tissue samples collected specifically for the trial to test new diagnostic methods or study how tumors respond to treatment at the cellular level. While this means an additional procedure, it contributes valuable information to cancer research and may provide insights into your specific cancer’s characteristics.

Throughout a clinical trial, ongoing diagnostic tests monitor your response to treatment and watch for side effects. These typically include regular imaging scans at specified intervals, blood tests before each treatment cycle, and periodic cystoscopy to directly examine the bladder. The frequency and type of monitoring are carefully designed into each trial protocol to ensure patient safety and gather meaningful data about the treatment being studied.^[10]